Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086881 | 1.00 | KDM4E (0.76) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL5074583 | 0.86 | APP (0.61) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL21505958 | 0.82 | ATM (0.77) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL29802060 | 0.81 | PTGDR2 (0.66) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL1250151 | 0.81 | ALDH1A1 (1.00) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL20615409 | 0.81 | SNCA (0.80) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL20603143 | 0.80 | SNCA (0.77) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30379008 | 0.80 | SNCA (0.77) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29801866 | 0.80 | PTGDR2 (0.65) | KDM4EALDH1A1MAPTATMSLC16A1 | |
| SCHEMBL29801783 | 0.80 | SNCA (0.73) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | KDM4E 1271/4885ALDH1A1 67/4885MAPT 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.